<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Compass Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/compass-therapeutics-inc</link>
<description>Latest news and press releases for Compass Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/compass-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835574278dffbe2df0ea1ba.webp</url>
<title>Compass Therapeutics Inc.</title>
<link>https://6ix.com/company/compass-therapeutics-inc</link>
</image>
<item>
<title>Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-23-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-to-announce-topline-secondary-endpoints-from-the-phase-23-companion-002-study-of-tovecimig-in-patients-with-biliary-tract-cancer</guid>
<pubDate>Fri, 24 Apr 2026 20:00:00 GMT</pubDate>
<description>Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 clinical study assessing tovecimig (a DLL4 x VEGF-A bispecific ant</description>
</item>
<item>
<title>Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-2025-financial-results-and-provides-corporate-update-10</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-2025-financial-results-and-provides-corporate-update-10</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold</description>
</item>
<item>
<title>Compass Therapeutics Provides Corporate Update</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-provides-corporate-update-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-provides-corporate-update-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of</description>
</item>
<item>
<title>Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics Announces Key Leadership Appointments</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-key-leadership-appointments-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-key-leadership-appointments-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-jp-morgan-2026-healthcare-conference-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-jp-morgan-2026-healthcare-conference-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics to Participate in Upcoming December Investor Events</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-december-investor-events-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-december-investor-events-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients</description>
</item>
<item>
<title>Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-presents-preclinical-data-ctx-10726-differentiated-pd-1-x-vegf</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-presents-preclinical-data-ctx-10726-differentiated-pd-1-x-vegf</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple</description>
</item>
<item>
<title>Compass Therapeutics to Participate in Upcoming November Investor Events</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-november-investor-events-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-november-investor-events-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company</description>
</item>
<item>
<title>Compass Therapeutics to Participate in Upcoming September Investor Events</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-september-investor-events-2025-08-26</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-september-investor-events-2025-08-26</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company</description>
</item>
<item>
<title>Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-pricing-upsized-120-million-public-offering-2025-08-13</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-pricing-upsized-120-million-public-offering-2025-08-13</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company</description>
</item>
<item>
<title>Compass Therapeutics Announces Proposed Public Offering</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-proposed-public-offering-2025-08-12</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-proposed-public-offering-2025-08-12</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company</description>
</item>
<item>
<title>Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-2025-second-quarter-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-2025-second-quarter-financial-results-and-provides</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been</description>
</item>
<item>
<title>Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-present-second-quarter-financial-results-and-provide-business</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-present-second-quarter-financial-results-and-provide-business</guid>
<pubDate>Fri, 08 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-jefferies-global-healthcare-conference-2025-05-28</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-jefferies-global-healthcare-conference-2025-05-28</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-2025-first-quarter-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-reports-2025-first-quarter-financial-results-and-provides</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC).</description>
</item>
<item>
<title>Compass Therapeutics to Participate in Upcoming May Investor Events</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-may-investor-events-2025-05-06</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-participate-upcoming-may-investor-events-2025-05-06</guid>
<pubDate>Tue, 06 May 2025 04:00:00 GMT</pubDate>
<description>BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
<item>
<title>Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-presents-data-enhanced-efficacy-ctx-471-combination-tovecimig</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-presents-data-enhanced-efficacy-ctx-471-combination-tovecimig</guid>
<pubDate>Mon, 28 Apr 2025 04:00:00 GMT</pubDate>
<description>CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with</description>
</item>
<item>
<title>Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer</title>
<link>https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-first-patient-dosed-investigator-sponsored-trial</link>
<guid isPermaLink="true">https://6ix.com/company/compass-therapeutics-inc/news/compass-therapeutics-announces-first-patient-dosed-investigator-sponsored-trial</guid>
<pubDate>Mon, 21 Apr 2025 04:00:00 GMT</pubDate>
<description>BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing</description>
</item>
</channel>
</rss>